Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GE180 PET Imaging of Neuroinflammation in AD and PD
NCT03702816Phase 2Terminated
- Start
- Dec 2018
- Primary completion
- Sep 2019
- Countries
- 1
01
Overview
A Phase 2 trial of flutriciclamide in Alzheimer's disease (AD), Parkinson's disease (PD), Mild Cognitive Impairment (MCI). Started Dec 2018; status: terminated.
02
Drugs
flutriciclamide
03
Conditions
Alzheimer's disease (AD)Parkinson's disease (PD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT03702816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03702816.